NIH Research Funding Opportunities

Recent NIH research funding opportunities will automatically be added to this page, so it will have the most up-to-date information. Please check this page regularly for NIH research funding opportunities. In addition, we recommend in subscribing to the NIH Guide to receive weekly announcements about funding opportunities.

Funding Opportunitites

Microbiome and Aging: Impact on Health and Disease (R01 Clinical Trial Not Allowed)

July 23rd, 2019

Funding Opportunity RFA-AG-20-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites projects focused on defining the factors that influence microbiome composition and functional characteristics during aging, understanding how the aging microbiome relates to the causes and pathophysiology of age-related chronic diseases, and development and testing of targeted interventions through diet, drugs, or live organisms. This FOA will accept basic mechanistic, preclinical studies in animal models and human studies leveraging existing human longitudinal cohorts.

Center of Excellence for Natural Product Drug interaction Research (U54, Clinical Trial Required)

July 23rd, 2019

Funding Opportunity RFA-AT-20-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Center of Excellence for Natural Product Drug Interaction Research to provide leadership in the study of natural product drug interactions. The ultimate goals of this program are to 1) clearly establish the clinical relevance of pharmacokinetic interactions from a select number of natural products, and 2) provide guidance and leadership to the broader research community on how best to research metabolism mediated drug interactions involving complex natural products. The Center will 1) identify, prioritize, source and characterize three to five natural products with potential to exhibit clinically significant interactions with commonly used medications; 2) perform all necessary preclinical work to characterize the interaction potential of the natural products including identifying the key mediators of any pharmacokinetic interaction as well as the mechanism(s) and magnitude of that interaction; 3) if warranted based on preclinical work, conduct rigorously designed clinical studies of these natural products to provide definitive data regarding the magnitude of any interaction in humans; 4) develop and maintain a repository for the data and methodology resources generated by this project as well as data generated by other researchers (especially the R21 grants funded through the companion RFA AT-20-001) regarding pharmacokinetic interactions involving natural products; and 5) provide ongoing guidance and leadership to the relevant research communities regarding how best to conduct research on pharmacokinetic natural product drug interactions; thereby facilitating better design of future research and ultimately better decisions regarding the concomitant use of medications and natural products.

Preclinical Screening for Natural Product Drug Interactions (Clinical Trial Not Allowed, R21)

July 23rd, 2019

Funding Opportunity RFA-AT-20-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that seek to identify natural products with the potential to inhibit or induce Phase I and Phase II drug metabolizing enzymes and drug transporters, thereby possibly contributing to pharmacokinetic interactions with other medications. These in vitro studies may include screening libraries of complex extracts and/or purified natural products in suitable medium to high throughput assays to identify potential interactions. They may also include isolation and identification of novel, or not commercially available, natural products within complex mixtures that exhibit pharmacokinetic interactions. This FOA is part of a larger investment from NCCIH that includes a U54 Center of Excellence for Natural Product Drug Interaction Research. It is expected that data generated in projects supported under this FOA will be uploaded and made publicly available through the data repository maintained by the U54 Center.

Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed)

July 22nd, 2019

Funding Opportunity RFA-AG-20-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites early-stage physicians and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. NIA is pursuing this initiative to recruit early-stage investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and be poised to change theory, practice, and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain.